Figure 1. CDDO-Me induces Nqo1 expression and activation
(a) Pharmacological mechanism of CDDO-Me in Nrf2 activation. (b)
Expression of Nqo1 mRNA in Hepa1c1c7 murine hepatoma cells after
treatment with the indicated concentrations of CDDO-Me for 6, 24, or 48
h determined using quantitative PCR (mean + S.D., duplicate). (c) NQO1
enzyme activity in Hepa1c1c7 cells after treatment with the indicated
concentrations of CDDO-Me (mean ± S.D., triplicate);
EC150 was calculated from the activities. (d) Expression
of Nqo1 mRNA in the livers of C57BL/6J mice after a single oral
administration of CDDO-Me at 3 mg・kg-1 or 10
mg・kg-1 (mean ± S.D.,
triplicate). (e) The
concentrations of plasma CDDO-Me in C57BL/6J mice after a single oral
administration of CDDO-Me at 3 mg・kg-1 or 10
mg・kg-1 (mean ± S.D., triplicate).